16th Oct 2017 16:52
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Ms E Walmsley | ||||||||||||||||||||||||||
b) | Position/status | Chief Executive Officer | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
1,866.43 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||
a) | Name | Mr R G Connor | ||||||||||||||||||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
900.310 £15.275 | ||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr L Debruyne | ||||||||||
b) | Position/status | President, Global Vaccines | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
713.484 £15.275 | ||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr S Dingemans | ||||||||||||||||||||||||||
b) | Position/status | Chief Financial Officer | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
2,151.842 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr N Hirons | ||||||||||||||||||||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
788.974 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr B McNamara | ||||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | ||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
151.926 $41.020 | ||||||
e) | Date of the transaction | 2017-10-12 | ||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr D S Redfern | ||||||||||||||||||||||||||
b) | Position/status | Chief Strategy Officer | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
1,051.446 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Ms C Thomas | ||||||||||||||||||||||||||
b) | Position/status | SVP, Human Resources | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
1,523.426 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||
a) | Name | Mr P C Thomson | ||||||||||||||
b) | Position/status | President, Global Affairs | ||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||
d) | Aggregated information
Aggregated volume Price |
481.816 £15.275 | ||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr D E Troy | ||||||||||||||||||||||||||
b) | Position/status | SVP & General Counsel | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
884.644 $41.020
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Dr P J T Vallance | ||||||||||||||||||||||||||
b) | Position/status | President, R&D | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume Price |
1,845.132 £15.275 | ||||||||||||||||||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
Related Shares:
Glaxosmithkline